Clinical Trial Update: Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating andecaliximab as add-on therapy to a TNF inhibitor and methotrexate regimen in adults with moderately to severely active rheumatoid art…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Andecaliximab
• METHOTREXATE (METHOTREXATE)

Snippet

Sponsor: Gilead Sciences | Conditions: Rheumatoid Arthritis | Phase 2 | Status: TERMINATED | Results posted: 2018-06-27